I. COMMENCED TRADING IN FEBRUARY

Company (Symbol)

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

INITIAL OFFERINGS

Cytovax Biotechnologies Inc. (Canada; TSE:CXB.A)1

11/16

2/21

1.67S

C$6

8.1

Acumen Capital Finance Partners Raymond James Ltd. Dlouhy Merchant Group First Associates Investments

C$10 US$6.5

C$9.25 US$6

Hemosol Inc. (Canada; HMSL; TSE:HML)2

1/18

2/28

7S

US$8.78

32.27

UBS Warburg LLC Dain Rauscher Wessels

US$61.5

US$56

Third Wave Technologies Inc. (TWTI)3

7/31

2/12

7.5S

$11

38.3

Lehman Brothers Inc. CIBC World Markets Corp. Fidelity Capital Markets Robert W. Baird & Co. Inc. Dain Rauscher Wessels

$82.5

$75.2

Total: $150.5M

Number of IPOs in February: 3

Average value of February IPOs: $50.17M

Number of IPOs for 2001: 5

Total raised in IPOs in 2001: $213.1M

Average value of IPOs in 2001: $42.62M

Notes:

1 Cytovax's underwriters have an overallotment option for 250,005 shares.

2 Hemosol's underwriters have an option to purchase an additional 1.05M shares to cover overallotments. The offering is being conducted in the U.S. and Canada.

3 Third Wave's underwriters have an overallotment option for another 1.125M shares.

FOLLOW-ON OFFERINGS

Company (Symbol)

Date

Date Filed

Shares/Comm.

Price Units (M)

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF)4

11/16

2/13

4.4S

C$1.90

N/A

HSBC Securities Inc. Roth Capital Partners Inc. (Placement agents)

C$8.3 US$5.46

N/A

AnorMED Inc. (Canada; TSE:AXO; OTC BB:ALXFF)5

1/23

2/6

1.5S

C$17

25.5

BMO Nesbitt Burns Inc. RBC Dominion Securities Inc. CIBC World Markets Corp. Raymond James Ltd.

C$25.5 US$16.92

C$24.2 US$15.6

Aviron Inc. (AVIR)6

12/18

2/2

4S (plus $200M in notes)

$50

30.5

Morgan Stanley Dean Witter J.P. Morgan Chase S.G. Cowen Securities Corp.

$400

$382.5

EntreMed Inc. (ENMD)7

2/6

2/27

1.45S

$18

18.1

Gerard Klauer Mattison & Co.

$26.1

$24.5

Praecis Pharmaceuticals Inc. (PRCS)8

1/26

2/15

7.6S

$24.562

48.78

CS First Boston (Co-lead) Salomon Smith Barney (Co-lead) CIBC World Markets Corp.

$186.7

$175.8

Notes:

4 AltaRex raised C$8.3M with the sale of 4.4M shares. No further details were disclosed.

5 AnorMED raised US$16.92M in the bought-deal financing conducted in Canada.

6 Aviron offered 4M shares of common stock and $200M in convertible notes. The underwriters have an overallotment option for 600,000 shares ­ 200,000 from selling stockholders, and 400,000 from the company ­ and $30M worth of notes.

7 EntredMed's underwriter has an option to purchase 100,000 additional shares to cover overallotments.

8 Praecis' underwriters exercised in full an overallotment option for approximately 1.1M additional shares. A selling stockholder also sold 750,000 shares, not included in the figures, at the same price.

Total: $635.18M

Number of follow-on offerings in February: 5

Average value of February follow-ons: $127.04M

Number of follow-on offerings in 2001: 7

Total raised in follow-ons in 2001: $687.27M

Average value of follow-ons in 2001: $98.2M

II. FILED AND PENDING

Company (Symbol/Proposed Symbol)*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

Acadia Pharmaceuticals Inc. (ACAD)1

12/21

5S

$13-15

15.8

Robertson Stephens Inc. (Co-lead) U.S. Bancorp Piper Jaffray (Co-lead)

$75

APBiotech (APBI; unit of Nycomed Amersham plc)2

10/3

18.2

$15-17

208.6

Morgan Stanley Dean Witter (Co-lead) Goldman, Sachs & Co. (Co-lead) Chase H&Q Salomon Smith Barney

$291.2

Athersys Inc. (ATHX)3

10/12

N/A

N/A

N/A

Credit Suisse First Boston Dain Rauscher Wessels ING Barings LLC

$115

BioMedicines Inc. (BIOS)4

11/3

N/A

N/A

15

UBS Warburg LLC U.S. Bancorp Piper Jaffray Pacific Growth Equities Inc.

$57.5

BioTissue Technologies AG (Germany)5

11/29**

1S

EUR27-34

N/A

Landesbank Baden-Wuerttemberg Equinet Securities AG Direkt Anlage Bank AG

EUR27 US$23

CombiMatrix Corp. (CLMX)6

11/22

N/A

N/A

N/A

Salomon Smith Barney (Co-lead) J.P. Morgan & Co. (Co-lead)

$100

diaDexus Inc. (DDXS)7

11/20

7S

$12-14

31.1

Lehman Brothers Inc. CIBC World Markets Corp. Fidelity Capital Markets

$91

DoubleTwist Inc. (DBLT)8

9/1

5S

$13-15

24.2

Lehman Brothers Inc. Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$70

DNA Sciences Inc. (DNAS)9

1/8

N/A

N/A

N/A

Lehman Brothers Inc. CIBC World Markets Corp. Dain Rauscher Wessels Inc.

$125

Dynavax Technologies Corp. (DVAX)10

12/5

N/A

N/A

N/A

Bank of America Securities LLC UBS Warburg (Joint leads)

$75

Kinetek Pharmaceuticals Inc. (Canada)11

10/20

N/A

N/A

N/A

N/A

N/A

NetGenics Inc. (NTGC)12

3/13/00

5.5S

$11-13

23.5

Chase H&Q UBS Warburg LLC

$66

PanBio Ltd. (Australia)13

2/28**

N/A

N/A

N/A

N/A

A$12 US$6.2

Seattle Genetics Inc. (SGEN)14

11/20

N/A

N/A

21.7

J.P. Morgan Securities Inc. CIBC World Markets Corp. Bank of America Securities LLC

$75

Senomyx Inc. (SNMX)15

2/21

N/A

N/A

17.4

Deutsche Banc Alex. Brown Bear, Stearns & Co. Inc. CIBC World Markets Corp.

$80

Xcyte Therapies Inc. (XCYT)16

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead) U.S. Bancorp Piper Jaffray (co-lead) Dain Rauscher Inc. First Security Van Kasper Inc.

$86.2

FOLLOW-ON OFFERINGS

Aastrom Biosciences Inc. (ASTM)17

12/7

6.35S

$1.27

33.84

N/A

$8.1

Alexion Pharmaceuticals Inc. (ALXN)18

10/6

N/A

N/A

N/A

N/A

$300

Atrix Laboratories Inc. (ATRX)19

2/15

4S

$25

13.64

N/A

$100

Cell Pathways Inc. (CLPA)20

2/8

N/A

N/A

N/A

N/A

$25

Charles River Laboratories Inc. (NYSE:CRL)21

2/15

3.5S

$24.85

39.4

Credit Suisse First Boston Corp. Lehman Brothers Inc.

$173.9

CV Therapeutics Inc. (CVTX)22

1/4

N/A

N/A

N/A

N/A

$400

Digene Corp. (DIGE)23

2/7

2.125S

$36.45

18.8

Goldman, Sachs & Co. S.G. Cowen Securities Corp. ABN AMRO Rothschild LLC

$77.5

InSite Vision Inc. (AMEX:ISV)24

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co. (Placement agent)

$40

Medarex Inc. (MEDX)25

12/22

N/A

N/A

N/A

N/A

$500

Microcide Pharmaceuticals Inc. (MCDE)26

2/12

N/A

N/A

N/A

N/A

$35

NeoTherapeutics Inc. (NEOT)27

1/3

N/A

N/A

N/A

N/A

$50

Packard BioScience Co. (PBSC)28

2/9

3S

$15

70.7

Merrill Lynch, Pierce, Fenner & Smith Credit Suisse First Boston J.P. Morgan Securities Inc. Bank of America Securities LLC Robert W. Baird & Co.

$45

Regeneron Pharmaceuticals Inc. (REGN)29

1/25

4S

$36.68

36.7

Merrill Lynch & Co. J.P. Morgan Chase & Co. Robertson Stephens Inc.

$146.7

Scios Inc. (SCIO)30

1/19

6.4S

$18.625

38.5

N/A

$120

The Medicines Co. (MDCO)31

1/8

4S

$16.953

29.3

J.P. Morgan & Co. (Co-lead) Robertson Stephens Inc. (Co-lead) CIBC World Markets Corp. U.S. Bancorp Piper Jaffray

$67.81

Transkaryotic Therapies Inc. (TKTX)32

12/13

N/A

N/A

N/A

N/A

$500

Xoma Ltd. (XOMA)33

11/17

10S

$11.25

N/A

N/A

$112.5

III. WITHDRAWN OR POSTPONED

INITIAL OFFERINGS

Company (Symbol/Proposed Symbol)*

Date Filed/Date Pulled

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

Xenogen Corp. (XGEN)34

9/00 2/13

7S

$9

26.9

UBS Warburg LLC CIBC World Markets Corp. Dain Rauscher Wessels

$63

Genometrix Inc. (GNMX)35

3/15 2/26

7S

$10-12

30.1

Lehman Brothers (Co-lead) Chase H&Q (Co-lead) Dain Rauscher Wessels Thomas Weisel Partners LLC

$77

Notes:

* Stock symbols for companies seeking to complete IPOs are proposed. **Denotes the date the item ran in BioWorld International.

1 Acadia's underwriters have an overallotment option for 750,000 shares.

2 APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

3 Athersys did not disclose any further details.

4 BioMedicines did not disclose any further details.

5 BioTissue's IPO filing is for Frankfurt's Neuer Markt. There is a greenshoe of 117,000 shares available to the underwriters.

6 CombiMatrix did not disclose any further details.

7 DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

8 DoubleTwist's IPO value, $70M, is based on the sale of 5M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 750,000 shares.

9 DNA Sciences did not disclose any further details.

10 Dynavax did not disclose any further details.

11 Kinetek's proposed IPO was filed in Canada. No further details were disclosed.

12 NetGenics' IPO's value, $66M, is based on the sale of 5.5M shares at $12 each, the midpoint of the expected price range. The underwriters have an overallotment option for 825,000 shares.

13 PanBio plans to raise A$12M in an IPO in Australia.

14 Seattle Genetics did not disclose any further details.

15 Senomyx did not disclose any further details.

16 Xcyte did not disclose any further details.

17 Aastrom's offering value, $8.1M, is based on the proposed maximum aggregate price of $1.27 per share for 6.35M shares.

18 Alexion filed a shelf registration to offer common stock, debt or warrants, up to a value of $300M.

19 Atrix filed to put 4M shares on the shelf. The value of the proposed offering, $100M, is based on the Feb. 15 closing stock price of $25.

20 Cell Pathways filed a shelf registration for the sale of $25M in common stock.

21 Charles River filed a registration statement to sell 7M shares, 3.5M from the company and another 3.5M from selling shareholders. The value of the offering, $173.9M, is based on the Feb. 15 closing stock price of $24.85.

22 CV filed a shelf registration to sell up to $400M in debt securities, preferred and common stock and warrants

23 Digene's offering is for 2.5M shares, 2.125M offered by the company and another 375,000 offered by selling stockholders. The value of the offering, $77.5M, is based on the sale of 2.125M shares at $36.45 each, the opening stock price on Feb. 7. The underwriters have an overallotment option for 375,000 shares.

24 InSite filed a shelf registration to sell $40M in stock

25 Medarex filed a shelf registration statement to offer up to $500M of common stock, preferred stock, warrants and debt securities.

26 Microcide filed a shelf registration for the sale of up to $35M in securities.

27 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M.

28 Packard filed to sell 10M shares, 3M from the company and 7M by stockholders. Certain stockholders granted the underwriters options to purchase an additional 1.5M shares to cover overallotments. The value of the offering, $45M, is based on the sale of 3M shares at an assumed price of $15 each.

29 Regeneron's underwriters have an overallotment option for an additional 600,000 shares. The value of the offering, $146.7M, is based on the closing stock price on Jan. 25.

30 Scios filed to sell 6.4M shares under a shelf registration. The value of the offering, $120M, is based on the Jan. 17 closing stock price of $18.625.

31 The value of The Medicines Co.'s offering, $67.812M, is based on the sale of 4M shares at the Jan. 8 opening stock price of $16.953. The underwriters have an overallotment option for 600,000 shares.

32 Trankaryotic Therapies filed a shelf registration statement for the sale of up to $500M in securities.

33 Xoma filed a shelf registration statement for the sale of up to 10M shares. The value, $112.5M, is based on the Nov. 16 closing price.

34 Xenogen postponed its IPO.

35 Genometrix withdrew its IPO.